Peptide therapy TikTok claims: what the science actually supports

What did @bigtwig_1 actually say?

The short version: he had significant elbow inflammation, suspected lateral epicondylitis (tennis elbow), went back on BPC-157 nasal spray, and reported being pain-free "within a few days." He also credited the peptide with helping him recover faster from training-related injuries in general.

That is a specific, testable set of claims. He is not claiming a cure. He is saying a peptide reduced his inflammation and got him back under heavy loads quickly. He is also transparent that he had used it before and returned to it, which at least tells you this is not a single anecdote from a first-time user chasing novelty. That context matters when evaluating the claim.

What he does not mention: dosing, injection frequency, whether he changed his training load, or whether he used any other interventions simultaneously. Those omissions make the claim harder to evaluate, not easier to dismiss.

Does the science back this up?

Partially, and with significant caveats. The animal literature on BPC-157 is genuinely impressive, but human trial data is nearly nonexistent, which is a real problem for anyone making strong claims.

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. In animal models, it has shown consistent effects on tendon repair, collagen synthesis, and inflammation modulation. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed multiple rat studies showing accelerated tendon-to-bone healing and reduced inflammatory markers after local and systemic BPC-157 administration. Chang et al. (2011, Journal of Applied Physiology) demonstrated that BPC-157 promoted tendon cell survival and outgrowth under oxidative stress conditions in vitro and in vivo.

The nasal route specifically is less studied than subcutaneous or intramuscular injection. Some researchers argue systemic absorption via intranasal administration is plausible given the peptide's stability in mucosal environments, but pharmacokinetic data in humans is absent. Claiming rapid relief "within a few days" via nasal spray is biologically possible based on mechanism, but unconfirmed by human trials.

What did they get wrong (or right)?

He got the mechanism directionally right. BPC-157 has legitimate preclinical support for tendon and connective tissue repair. Framing it as something that reduces inflammation and speeds recovery from a repetitive strain injury is consistent with what the animal data suggests it does.

What he gets wrong, or at least oversimplifies, is the implied certainty. Saying "I have no issues, no inflammation, no pain. Just amazing" treats a personal experience as proof of efficacy. It is not. Lateral epicondylitis is notoriously self-limiting. Studies like Smidt et al. (2002, The Lancet) found that tennis elbow often resolves on its own within a year, and even cortisone injections showed no long-term benefit over watchful waiting. The possibility that he simply rested enough, that his inflammation was already subsiding, or that his training modification did the work cannot be ruled out from a single self-report.

He also does not flag that BPC-157 is not FDA-approved for human use, has no established dosing protocol in humans, and is obtained outside conventional medical channels. For a 440K-view video, that is a meaningful omission.

What should you actually know?

BPC-157 sits in an unusual regulatory space. It is not a scheduled substance, but the FDA has not approved it as a drug or dietary supplement. The Peptide Society and compounding pharmacies operate in a gray zone. As of 2023, the FDA issued guidance restricting BPC-157 from use in compounded medications, though enforcement has been inconsistent.

If you are dealing with chronic tendon inflammation, the evidence base for physical therapy, particularly eccentric loading protocols for epicondylitis (Svernlov and Adolphson, 2001, Scandinavian Journal of Medicine and Science in Sports), is actually stronger in humans than anything available for BPC-157. That is not a knock on BPC-157's potential. It is just a fact about where the research currently stands.

Anyone considering peptide therapy for a musculoskeletal complaint should have that conversation with a licensed provider who can assess whether the underlying issue is structural, inflammatory, or both. Self-diagnosis and self-administration based on a TikTok video carries real risk, including delaying diagnosis of something that actually requires imaging or surgical evaluation.